
Monopar Therapeutics Inc.: updates and filings
Price
$69.00
November 20, 2026Market cap $591M
What Ploutos Investor adds for Monopar Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
August 2026
May 2026
March 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 12, 2026Results of operationsForm8-K
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 22, 2026FORM S-8 POSFormS-8 POS
- Jul 22, 2026FORM S-8 POSFormS-8 POS
- Jul 22, 2026FORM S-8 POSFormS-8 POS
- Jul 22, 2026FORM S-8 POSFormS-8 POS
- Jul 22, 2026Shares registered for employeesFormS-8
- Jul 22, 2026Regulation FD disclosureForm8-K
- Jul 10, 2026Filing (amendment)Form144/A
- Jun 30, 2026Regulation FD disclosureForm8-K
- Jun 26, 2026Regulation FD disclosureForm8-K
- Jun 23, 2026Shareholder voteForm8-K
- May 29, 2026Regulation FD disclosureForm8-K
- May 19, 2026Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- May 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 12, 2026 | 8-K | Results of operations | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 22, 2026 | S-8 POS | FORM S-8 POS | Document |
| Jul 22, 2026 | S-8 POS | FORM S-8 POS | Document |
| Jul 22, 2026 | S-8 POS | FORM S-8 POS | Document |
| Jul 22, 2026 | S-8 POS | FORM S-8 POS | Document |
| Jul 22, 2026 | S-8 | Shares registered for employees | Document |
| Jul 22, 2026 | 8-K | Regulation FD disclosure | Document |
| Jul 10, 2026 | 144/A | Filing (amendment) | Document |
| Jun 30, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 26, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 23, 2026 | 8-K | Shareholder vote | Document |
| May 29, 2026 | 8-K | Regulation FD disclosure | Document |
| May 19, 2026 | 8-K | Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| May 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 18, 2015.
The full analysis
What do Monopar Therapeutics's filings show?
The filings are where every one of Monopar Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.